TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) Short Interest Up 70.4% in August

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW) saw a significant increase in short interest in August. As of August 14th, there was short interest totaling 20,535 shares, an increase of 70.4% from the July 30th total of 12,050 shares. Based on an average daily trading volume, of 3,313 shares, the short-interest ratio is presently 6.2 days.

TriSalus Life Sciences Trading Up 2.5%

TLSIW opened at $0.89 on Wednesday. The stock has a 50-day moving average of $0.86 and a 200-day moving average of $0.95. TriSalus Life Sciences has a 52-week low of $0.44 and a 52-week high of $2.19.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in TLSIW. Cerity Partners LLC bought a new position in TriSalus Life Sciences during the fourth quarter worth $1,374,000. Citadel Advisors LLC grew its position in TriSalus Life Sciences by 439.0% in the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock worth $199,000 after purchasing an additional 103,336 shares during the last quarter. Fort Baker Capital Management LP bought a new position in shares of TriSalus Life Sciences during the 4th quarter worth about $44,000. Finally, Aristeia Capital L.L.C. acquired a new position in shares of TriSalus Life Sciences during the fourth quarter valued at about $43,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.